The trials yielded mixed results and provided only partial validation for a neurotrophic- based PD treatment, while underscoring multiple issues raised by this type of therapy, including toxicity, inconsistent effectiveness, and the likely need to deliver drug to both the cell body area and terminal fields
doi: 10.3389/fmolb.2022.852911 Received 11 January 2022 Accepted 07 February 2022 Published 04 March 2022 Volume 9 - 2022 Edited by Shen Zhang, Reproductive and Genetic Hospital of CITIC-Xiangya, China Reviewed by Qun Zhao, Dalian Institute of Chemical Physics (CAS), China Yanbo Pan, Karolinska Institutet (KI), Sweden Updates Copyright 2022 Dionne and Gingras
135 MohammadiA.Hosseinzadeh ColagarA.KhorshidianA.AminiS
Experience the benefits of glutathione IV therapy without stepping out the door
Cellular NAD+ levels decline with age and metabolic stress, which may contribute to reduced mitochondrial function and impaired cellular resilience [8]